Wed Sep 25 04:14:04 UTC 2024: ## Senate Grills Novo Nordisk CEO on High Prices of Ozempic and Wegovy
**Washington, D.C.** – A heated exchange took place in the Senate this week as lawmakers grilled the CEO of Novo Nordisk, the pharmaceutical company behind the blockbuster weight-loss drugs Ozempic and Wegovy. Senator Bernie Sanders led the charge, accusing the company of “greed” and demanding answers about the exorbitant pricing of these medications.
Senator Sanders, a vocal critic of high drug prices, questioned the CEO about the drastic price increase for Wegovy, which is a higher dose of the same drug as Ozempic and is used for chronic weight management. The company defended its pricing, citing the drugs’ effectiveness and the high cost of research and development.
However, senators from both sides of the aisle expressed concern about the affordability of these drugs for millions of Americans struggling with obesity. They questioned the CEO about the company’s profits and how much of the drug’s price goes towards research and development versus profit.
The CEO faced intense scrutiny from lawmakers, who cited the company’s record-breaking profits and argued that the high prices are not justified by the drug’s innovation. This grilling comes as the debate over drug pricing continues to be a hot topic in American politics.
The hearing served as a stark reminder of the ongoing struggle for affordable medication in the United States. It remains to be seen whether the Senate will take action to regulate drug prices and ensure access to essential medication for all Americans.
First Piper 